Compare CCO & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCO | RAPP |
|---|---|---|
| Founded | 1995 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2005 | 2024 |
| Metric | CCO | RAPP |
|---|---|---|
| Price | $2.08 | $29.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $2.10 | ★ $47.80 |
| AVG Volume (30 Days) | ★ 2.2M | 375.1K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,569,344,000.00 | N/A |
| Revenue This Year | $6.76 | N/A |
| Revenue Next Year | $4.42 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 54.21 | N/A |
| 52 Week Low | $0.81 | $6.43 |
| 52 Week High | $2.09 | $42.27 |
| Indicator | CCO | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 64.60 | 55.68 |
| Support Level | $2.00 | $28.03 |
| Resistance Level | $2.09 | $31.52 |
| Average True Range (ATR) | 0.07 | 1.95 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 90.63 | 59.02 |
Clear Channel Outdoor Holdings Inc is a provider of out-of-home advertising solutions. The company offers advertisers an opportunity to reach mass audiences across various high-traffic public spaces, by using its diverse portfolio of assets including roadside billboards, street furniture, and airport displays. Its reportable segments are; America (U.S. operations excluding airports), Airports (U.S. and Caribbean airport operations), and Other. A majority of its revenue is generated from the America segment which generates revenue from the sale of advertising on printed and digital out-of-home advertising displays such as bulletins, posters, street furniture, and others. Geographically, the company generates maximum revenue from the United States followed by Singapore.
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.